AziLsartan treatMent as a swItch strateGy for improvement of uncontrolled Hypertension and blood pressure variabiliTY

AziLsartan treatMent as a swItch strateGy for improvement of uncontrolled Hypertension and blood pressure variabiliTY - ALMIGHTY

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012586

Enrollment

230

Registered

2013-12-16

Start date

2013-07-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hyertension

Interventions

azilsartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: 1.Secondary hypertension 2.Grade III hypertension according JSH2009 3.Congestive heart failure 4.Severe valvular heart disease 5.Myocardial infarction and cerebellar infarction within 6 months 6.Chronic atrial filtration 7.Malignant arrhythmia 8.Renal insufficiency (=>serum creatinine 2mg/dl) 9.Severe liver disease 10.Chronic inflammatory disease 11.Malignant disease (life prognosis less than 6 months) 12.Patients receiving other RAS inhibitors 13.Patients who are determined by the investigators to be unsuitable

Design outcomes

Primary

Measure	Time frame
Change in day-by-day blood pressure vriablity after azilsartan treatment	—

Countries

Japan

Contacts

Public ContactToru Miyoshi

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Cardiovascular Medicine

miyoshit@cc.okayama-u.ac.jp086-235-7351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026